Alcohol Abuse Causes Liver Injury
=================================

Heavy drinking is a major cause of liver disease worldwide ([@B75]). Current trends indicate that, in the United States, between 2007 and 2014, alcohol-induced liver disease (AILD) became the second most frequent cause of cirrhosis and hepatocellular carcinoma (HCC)-related mortality after non-alcoholic fatty liver disease (NAFLD) ([@B54]). Fatty liver (steatosis) is the earliest response to excessive drinking in 90% or more of alcohol abusers ([@B75]; [@B117]). Steatosis is characterized by excessive deposition of fat, seen microscopically as intracellular lipid droplets (LDs). These are hydrophobic islands of stored fat, each surrounded by a phospholipid monolayer, which, itself, harbors specific proteins that maintain LD integrity. Under the microscope, LDs can be seen suspended alone in the soluble cytoplasm (cytosol) or in physical contact with other membranous organelles, including the endoplasmic reticulum (ER), from which LDs are believed to originate ([@B78]; [@B30]; [@B15]). LDs also interact with mitochondria, lysosomes, peroxisomes, and membranes of the Golgi apparatus ([@B4]). Each of the latter organelles has a functional interaction with LDs, the extent of which appears to depend on the cell's lipid content ([@B59]).

In this review, the terms "autophagy" and "lipophagy" will, be used interchangeably or together. The two are closely-linked, as LDs are taken up and degraded with other cellular constituents, by "bulk autophagy." During "true lipophagy," LDs are selectively taken up and degraded. In addition, the classical autophagy/lipophagy pathway, mentioned in the Abstract has some non-canonical variations to be described herein.

Aild Is Linked to Ethanol Oxidation
===================================

The liver sustains the greatest injury after excessive drinking because it is the principal site of ethanol oxidation (metabolism) ([@B68]; [@B76]), as depicted in [Figure 1](#F1){ref-type="fig"}. The bulk of hepatic ethanol oxidation is catalyzed by alcohol dehydrogenase (ADH) and cytochrome P450 2E1(CYP2E1). Catalase, an enzyme, which inhabits peroxisomes and is abundant in liver, has an accessory function in hepatic ethanol oxidation, but a more prominent role in brain ethanol metabolism ([@B123]). ADH, the primary oxidative enzyme, is located in the liver cytosol (soluble cytoplasm). ADH has a high catalytic efficiency (K~cat~) and a high affinity (K~m\ ethanol~ = 1--2 mM) for ethanol as a substrate. CYP2E1 is predominantly associated with the membranes of the smooth ER. It has a lower affinity for ethanol (K~m\ ethanol~ = 10--20 mM) and a lower K~cat~ than ADH. All three enzymes oxidize ethanol to generate acetaldehyde, which is toxic because it is highly reactive and covalently binds to proteins, lipids and nucleic acids ([@B47]; [@B22]; [@B9]). In hepatocytes, acetaldehyde's toxicity is minimized because it is rapidly oxidized to acetate by the mitochondrial aldehyde dehydrogenase2 (ALDH2). Both ADH-catalyzed ethanol oxidation to acetaldehyde and ALDH2-catalyzed acetaldehyde oxidation to acetate utilize nicotinamide adenine dinucleotide (NAD^+^) as a hydrogen and electron acceptor. Together, both reactions generate excess quantities of NADH, which lowers the intracellular NAD^+^/NADH ratio, also known as the cellular redox potential. The latter change in redox initiates significant metabolic shifts toward reductive synthesis by accelerating the synthesis and slowing the oxidation of fatty acids, thereby exacerbating steatosis. In addition, ethanol oxidation stimulates fatty acid biosynthesis by enhancing *de novo* synthesis of lipogenic enzymes, the syntheses of which are governed by activation of three transcription factors: the sterol regulatory element binding protein-1c (SREBP-1c), the carbohydrate response element binding protein (ChREBP) and early growth response-1 (Egr-1). We and others have described the induction and regulatory features of these factors in other articles and reviews ([@B119]; [@B64]; [@B103]; [@B101]; [@B117]).

![Ethanol metabolism and hepatic oxidant stress. Ethanol is oxidized principally in liver hepatocytes by ADH, CYP2E1, and catalase to acetaldehyde (Ach). Ach is a highly reactive intermediate that, itself, covalently binds to protein or can undergo secondary reactions to form MAA (see text). CYP2E1 is induced by ethanol and produces radicals, including superoxide and hydroxyl radicals, which by themselves are reactive and can undergo secondary reactions with PUFA, producing ROS and RNS as defined in this figure and in the text. The latter reactive molecules can also form adducts with proteins.](fphar-10-00495-g001){#F1}

CYP2E1, the other major ethanol metabolizing enzyme is unique in two ways: (1) The enzyme is induced by ethanol, which elevates CYP2E1's intracellular content ([@B65], [@B66]; [@B81]), thereby accelerating the overall rate of ethanol oxidation; (2) CYP2E1 possesses a unique catalytic cycle, coupled with a broad substrate specificity. The latter properties allow the enzyme to produce, not only higher levels of acetaldehyde but also greater quantities of other reactive oxygen species (ROS), including hydroxyethyl radicals (•CH~3~CH~2~OH), hydroxyl radicals (•OH), and superoxide anions (O~2~^−^). Superoxide can undergo secondary reactions with nitric oxide to form peroxynitrite (OONO^−^), which can covalently bind to tyrosine residues on proteins ([@B77]). All the aforementioned reactive species are unstable, but they heighten oxidant stress in the hepatocyte to enhance hepatocellular damage ([@B114]; [@B116]) (also see Takahashi). It is now clear that development of alcohol-induced fatty liver is the "first hit" that propagates injury, as described in the next section.

Metabolic Sources of Alcohol-Induced Hepatic Lipids and Their Hepatotoxicity
============================================================================

Alcohol-induced fatty liver was reported in humans ([@B10]) decades before the metabolic pathways affected by heavy drinking were revealed and well before it was discovered that certain fatty acids are hepatotoxic ([@B83]). Hepatic fatty acid (and lipid droplet) accumulation after alcohol abuse arises from: (1) accelerated hepatic lipogenesis ([@B119]; [@B118]); (2) enhanced fatty acid import into the liver from the plasma ([@B113]); (3) defective secretion of lipoproteins (e.g., very low density lipoproteins VLDLs) from the liver into the plasma, resulting in their hepatic retention ([@B53]); (4) reduced fatty acid oxidation (FAO) by mitochondria ([@B31]); and now, (5) decelerated lipophagy ([@B79]; [@B87]).

Steatosis from heavy drinking elevates intrahepatic levels of saturated and polyunsaturated fatty acids (PUFA). The latter are particularly reactive, because their double bonds, allow them to combine with hydroxyl radicals (•OH) derived from ethanol oxidation and/or mitochondrial respiration, to form lipid peroxides. These undergo subsequent modifications, including the iron-driven Fenton reaction and peroxide fragmentation to produce highly reactive lipid aldehydes, including 4-hyroxynonenal (4-HNE) and malondialdehyde (MDA), each of which covalently binds to proteins ([@B40]). Acetaldehyde, generated from ethanol oxidation can also react with MDA to form a larger, highly reactive hybrid molecule, malodialdehyde-acetaldehyde (MAA) that binds to proteins, forming MAA adducts ([@B110], [@B109]; [Figure 1](#F1){ref-type="fig"}) Proteins that bear such adducts exhibit altered biological function as well as proinflammatory and profibrogenic properties that can exacerbate liver injury beyond simple steatosis ([@B52], [@B51]; [@B108]). It is also noteworthy that earlier *in vitro* studies revealed that substoichiometric concentrations of acetaldehyde (Ach) alone can form adducts with a specific lysine residue on the alpha subunit of tubulin to disrupt its polymerization into functional microtubules ([@B98]) These findings suggest that metabolically-derived Ach has similar properties *in vivo*, which may explain how chronic ethanol consumption disrupts vesicle trafficking in hepatocytes during autophagy. [Figure 2](#F2){ref-type="fig"} depicts such a scenario.

![Postulated mechanism by which acetaldehyde impairs microtubule function. Acetaldehyde (Ach) is generated from ethanol oxidation. Due to its high reactivity, it can, form adducts with the α-subunit of tubulin, to inhibit microtubule (MT) polymerization. Such inhibition impairs MT-dependent processes, including the movement of LD-bearing autophagosomes to lysosomes for degradation of LDs.](fphar-10-00495-g002){#F2}

LD Catabolism
=============

Until 2009, it was held that LDs are degraded by lipases in the cytosol and by the lysosomal acid lipase (LAL), but do not undergo macroautophagy. That concept was discarded after [@B96] demonstrated the macroautophagic degradation of LDs. These investigators also added the term, "lipophagy" to the list of autophagic organelle degradation pathways. That list includes mitophagy (mitochondria) ([@B60]), pexophagy (peroxisomes) ([@B45]), ERphagy or reticulophagy (endoplasmic reticulum), ([@B86]) ribophagy (ribosomes) ([@B1]) nucleophagy (nuclei) ([@B74]), lysophagy (lysosomes) ([@B41]), and in photosynthetic cells, chlorophagy (chloroplasts) ([@B42]; [@B111]).

[@B88] reviewed the multiple pathways by which LDs are degraded in liver cells. These are depicted in [Figure 3](#F3){ref-type="fig"}. Macrolipophagy is the canonical vesicular pathway during which LDs (or portions thereof) are selectively sequestered in autophagosomes, which are then trafficked by microtubules to fuse with lysosomes, forming autolysosomes in which the LDs_is/are degraded. During microlipophagy, LDs directly interact with (or are engulfed by) lysosomes in an endocytosis-like manner, for direct lipolysis of the LD contents. Chaperone-mediated autophagy (CMA), carries out the selective lysosomal degradation of specific proteins that reside on the LD membrane. Two such proteins are the perilipins 2 and 3 (PLIN2 and PLIN3) ([@B46]) These proteins are targeted by CMA to the lysosome because each carries, in its primary sequence, a specific pentapeptide (lys-phe-glu-arg-gln or KFERQ), which is recognized by and binds to the cytosolic form of the 70 kDa heat shock constitutive protein, (Hsc70) a chaperone, that directs each PLIN to the lysosomal membrane. There, the lysosome-associated membrane protein 2A (LAMP2A) facilitates each protein's internalization and degradation. The removal and degradation by CMA of PLINS from the LD membrane enhances recruitment of cytosolic lipases, including the cytoplasmic adipose triglyceride lipase (ATGL) to initiate lipolysis of the LD contents ([@B57]). In the context of this review, it is noteworthy that, prior to its degradation by CMA, PLIN 2 is phosphorylated by the energy-sensing adenosine monophosphate-activated kinase (AMPK) ([@B46]). The kinase is activated by nutrient deficit but inactivated by chronic alcohol consumption ([@B118]; [@B120]). The reader should note that [Figure 3](#F3){ref-type="fig"} identifies this and other specific steps in the lipophagic pathways illustrated, that are impaired by alcohol abuse.

![Schematic of lipophagy pathways. Shown are the three major lipophagic pathways: macrolipophagy **(right)**, microlipophagy **(left)** and chaperone-mediated autophagy of lipid droplet proteins **(top center).** Details of each pathway are described in the text. Direct lipolysis by cytosolic lipases of a lipid droplet is shown in the **center**. Figure reproduced from Figure 1 by [@B88] with permission. Note: The figure shows steps in the pathways that are inhibited by ethanol consumption. These are denoted by the numbered symbols indicated by (EtOH.) In **(1)** ethanol consumption blocks CMA by inhibiting AMPK; in **(2)** ethanol consumption prevents lysosome biogenesis by inhibiting TFEB; in **(3)** ethanol consumption impairs lipolysis by inhibiting ATGL and HSL; in **(4)** ethanol consumption blocks mitochondrial fatty acid oxidation by causing mitochondrial damage and inactivating PPAR- alpha. Details of each are described in the text.](fphar-10-00495-g003){#F3}

PLIN2 is also ubiquitylated and degraded by the ubiquitin-proteasome system (UPS) ([@B115]). Ubiquitylation is a post-translational modification, during which polymers of ubiquitin, an 8.5 kDa polypeptide, are covalently attached to protein substrates at their free NH~2~-termini or at the epsilon-amino groups of their internal lysine residues. The polyubiquitin chain is a signal for degradation of the protein substrate by the 26S proteasome ([@B17]; [@B16]; [@B5]; [@B18]). Evidence indicates that the UPS regulates the content of PLIN2 in the cytosol by degrading its cytosolic form, but after it is localized in the LD membrane, PLIN2 evades UPS-catalyzed proteolysis ([@B99]) but is subject to degradation by CMA ([@B46]).

LD Size Influences Its Mode of Catabolism
=========================================

In liver cells LD size varies widely from about 60 nanometers to more than 20,000 nanometers (20 microns) in diameter. Larger LDs are readily seen in liver histology sections from ethanol-fed rodents ([@B25]) and in liver biopsies of people with alcohol use disorders (AUDs) ([@B107]). Evidence now indicates that LD size influences which lipolytic pathway initiates LD breakdown. A recent investigation by [@B84] (AASLD abstract; MS under review) revealed that autophagosomes and multivesicular bodies (MVB)/late endosomes, selectively sequester smaller-sized LDs, while larger LDs more frequently interact with the cytosolic adipocyte triglyceride lipase, (ATGL) the rate-limiting enzyme in triglyceride lipolysis. Thus, ATGL appears to preferentially lipolyze the contents of larger LDs, reducing them to sizes that allow their terminal sequestration into autophagosomes. These findings imply that the breakdown of very large LDs, such as those seen in livers with alcohol-induced macrovesicular steatosis proceeds by a sequential lipolysis-to-lipophagy mechanism.

The physio-biochemical causes of alcohol-induced LD enlargement can be traced partially to disruption of LD breakdown. [@B70] reported that ethanol-induced LD enlargement is, in part, the result of decreased lipolysis, which coincides with a significant reduction in the phosphatidylcholine (PC) to phosphatidylethanolamine (PE) ratio in LD membranes of ethanol-fed animals. LDs that lack sufficient PC to shield internal lipid stores exhibit a tendency to fuse with each other, thereby creating enlarged LDs that can occupy the entire hepatocyte, pushing the nucleus to the periphery ([@B37]; [@B58]; [@B117]). Furthermore, the reduction in LD surface PC:PE ratio on these enlarged LDs is associated with higher contents of PLIN2 and PLIN3 on the LD membrane. LD-associated PLINs confer structural integrity to the LD because they potently inhibit lipase activity ([@B8]; [@B39]). The latter findings have been substantiated *in vitro* by studies conducted with liposomes, which model LDs, and were synthesized with PC:PE ratios identical to those detected in hepatic LDs of ethanol-fed rats. These analyses revealed that ethanol-induced changes in the LD phospholipid composition, contribute directly to quantitative changes in proteins that associate with the LD surface. Therefore, reducing the ratio of PC to PE increases PLIN2 and PLIN3 binding to the LD membrane ([@B70]). Comparable results were obtained when NIH 3T3 and AML12 cells were exposed to choline-deficient media, which also decreases the PC:PE ratio of LDs ([@B70]). Their data showed increased association of PLINs, and other specific proteins, with LDs. Taken together, these studies indicate that ethanol-induced phospholipid alterations on the LD surface (PC:PE ratio) directly impacts LD size and number by altering the LD surface proteome and inhibiting lipolytic pathways, including lipophagy.

Autophagy Is Regulated by Ethanol Oxidation
===========================================

Active autophagy is essential for cell survival because it yields energy while it recycles substrates required for macromolecular synthesis. Whether ethanol exposure stimulates or slows autophagy *in vivo* or *in vitro* depends on the duration of ethanol consumption/exposure, the amount of ethanol administered, and the manner in which it is administered to animals or cells ([@B102], [@B105]) Acute ethanol consumption, also called binge drinking, occurs when a large amount of alcohol is imbibed in a single bolus or at multiple times during a short (usually two to 12 h) time period ([@B121]). Acute ethanol administration to naïve animals, usually performed by gastric intubation (gavage), accelerates hepatic autophagy ([@B20]; [@B105]). In contrast, feeding the ethanol liquid diet ([@B67]) to rodents for several weeks, retards hepatic autophagy, as judged grossly by liver enlargement (hepatomegaly), which reflects lipid and protein accumulation ([@B3]; [@B23]) and biochemically by the hepatic accumulation of two autophagy marker proteins: one is p62/SQSTM (sequestosome), an adaptor protein and lysosome substrate. The other is the lipidated form II of microtubule-associated protein 1 light chain 3 (LC3II), a classical marker of autophagosome content ([@B82]; [@B105]; [@B79]).

Autophagy in Cultured Cells
---------------------------

We measured autophagy in ethanol-exposed recombinant VL-17A^ADH+/CY\ P2E1+^ cells that metabolize ethanol ([@B27]). Our studies revealed that 24 h or longer exposure of cells to 50 mM ethanol inhibits autophagy. This is due, in part, to the ethanol-induced depletion of lysosomes, which decrease by 50% while autophagosome numbers (seen microscopically as GFP-LC3II-positive puncta) nearly double in the same time period ([@B102]) The ethanol-induced rise in autophagosomes does not occur in parental Hep G2 cells, which express neither ADH nor CYP2E1. Similarly, autophagy proceeds normally when ethanol-treated VL-17A cells are co-treated with 4-methylpyrazole (4-MP) which blocks ethanol oxidation. LC3II levels also remain unchanged when reactive metabolites generated by ethanol oxidation are scavenged, by co-treating VL-17A cells with glutathione ethyl ester ([@B102]). The latter findings clearly indicate that blocking acetaldehyde/ROS formation or enhancing the removal of these metabolites avoids the disruptive effects of ethanol oxidation on autophagy in ethanol-metabolizing VL-17A cells.

Autophagy *in vivo*
-------------------

More recent studies by [@B35] showed that autophagy either slows down or proceeds normally in response to the level of acetaldehyde flux generated during ethanol metabolism. They report that ethanol-fed mice carrying the ALDH2 transgene exhibit significantly lower levels of blood and liver acetaldehyde than identically-treated control mice, carrying the friendly virus B (FVB) viral vector, without the ALDH2 transgene. These findings suggest that ALDH2 transgenic mice clear acetaldehyde more rapidly than FVB control mice. Livers from ethanol-fed ALDH2 transgenic mice exhibit normal (control) levels of autophagy markers and a threefold reduction in hepatic triglycerides, compared with ethanol-fed FVB mice.

*In vitro* studies by these investigators revealed that direct ethanol (100 mM) or acetaldehyde (100 or 500 μM) exposure to ethanol-metabolizing VA-13^ADH+/CY\ P2E1−^ cells, suppressed intracellular autophagy, while exposure to each compound caused increased cellular expression of interleukin-6 (IL-6), a pro-inflammatory marker ([@B76]). Both the latter responses were alleviated when ethanol or acetaldehyde-treated VA-13 cells were co-treated with the autophagy activator rapamycin or with the ALDH2 activator Alda-1. Their findings suggest that autophagy/lipophagy is suppressed by metabolically-derived acetaldehyde. However, accelerated acetaldehyde clearance by higher intrahepatic levels of ALDH2 or by Alda-1-activated ALDH2, prevents ethanol/acetaldehyde-elicited autophagy retardation and liver cell injury. The striking reduction in liver triglycerides in ethanol-fed ALDH2 transgenic animals, suggests that the reduction in the amount of metabolically-generated acetaldehyde allows lipophagy and subsequent lipolysis to proceed normally.

Other Metabolic Considerations
------------------------------

The study just described prompts the question of whether enhanced acetate formation due to accelerated acetaldehyde oxidation contributes to autophagy activation. This appears unlikely, as we reported that direct exposure of VL-17A cells to 10 mM acetate causes no change in LC3II content. In contrast, when we expose VL-17A cells to 100 μM acetaldehyde, LC3II content rises, indicating autophagy retardation ([@B102]). Acetate is metabolically converted to acetyl CoA, a substrate for acetyltransferases, which catalyze the attachment of acetyl groups to lysine side chains on proteins ([@B29]). There are reports that acetylation of transcription factor EB influences its activity as the principal regulator of autophagy and lysosome biogenesis (discussed later in this review). However, published findings report mixed results. Some declare that acetylation of TFEB reduces its activity ([@B2]), while others assert that this modification activates the transcription factor ([@B61],[@B62]). For now, our data indicate that excess acetate, by itself, does not influence autophagy, but studies designed to critically examine the incorporation of acetate derived directly from ethanol oxidation into acetyl CoA and subsequently into acetylated proteins, will likely reveal a more definitive answer to this question.

Chronic Ethanol Consumption/Exposure Disrupts Lipophagy
=======================================================

There is solid evidence that, similar to affecting bulk autophagy, chronic ethanol consumption retards the lipophagic clearance of LDs. An *in vitro* study by [@B73] used alcohol-metabolizing WIFB cells to demonstrate that ethanol oxidation is strongly associated with impaired fat clearance and accumulation of LDs and of the lipid droplet protein PLIN2 (a.k.a. adipocyte differentiation related protein; ADRP in this paper). Their findings led them to suggest that ethanol metabolism retards lipophagy. Related to this report are several others that similarly, indicate that ethanol consumption by rodents not only disrupts the structural integrity of liver lysosomes ([@B21], [@B25]; [@B49], [@B48]), but also retards lysosome biogenesis *in vivo* ([@B50]; [@B12]) and in cultured cells ([@B102]).

*Ex vivo* Studies Show Lipophagy Impairment by Chronic Ethanol Administration
-----------------------------------------------------------------------------

[@B79] reported that the clearance of LDs (as judged by triglyceride disappearance), in hepatocytes from ethanol-fed rats was slower than that in cells from pair-fed control animals. The latter finding was associated with lower intracellular levels of the active (phosphorylated) form of dynamin-2 (Dyn-2), a GTPase that catalyzes the scission of autolysosomes to sustain autophagic lysosome regeneration, a process that essentially "recycles" lysosomes from pre-existing autolysosomes ([@B14]). They also reported that hepatocytes from ethanol-fed rats contained lower levels than controls of the phosphorylated form of Src kinase, which phosphorylates, and activates Dyn-2. Consequently, hepatocytes of ethanol-fed rats contained 42% fewer lysosomes and 40--66% higher levels of the autophagy marker/substrate proteins LC3II and p62 than cells from pair-fed control animals. Their data indicate an ethanol-elicited retardation of LD degradation that likely results, in part, from faulty lysosome regeneration, adding to the previously-reported ethanol-induced decline in *de novo* lysosome biogenesis in livers of ethanol-fed rats ([@B50]). Similar findings were recently reported in mice ([@B11],[@B12]), using the chronic ethanol feeding, followed by ethanol binge (NIAAA) feeding model of ethanol administration ([@B6],[@B7]; [@B33]). The latter feeding regimen to rodents reportedly recapitulates the drinking patterns, as well as the degree of liver injury in humans with AUDs.

Related work by [@B87] found that chronic ethanol consumption impairs Rab7, a small GTPase that facilitates lysosome recruitment to the LD. They report that hepatocytes from ethanol-fed rats exhibit lysosome clustering, suggesting a partial blockage of lysosome mobility and dispersion. They also detected a 50% decline in Rab7 activity in fasted (lipophagy-activated) hepatocytes from ethanol-fed rats, compared with identically-treated hepatocytes from control rats. Together, their findings indicate that ethanol exposure negatively affects GTPases that have accessory roles in lysosome function. These findings further support the notion that ethanol consumption significantly disrupts the degradative (lysosomal) phase of lipophagy. Their reported findings of ethanol-induced disruption in lysosome mobility also indicate an ethanol-elicited decline in trafficking of these organelles by microtubules. As mentioned earlier, acetaldehyde, the primary oxidation product of ethanol oxidation, blocks polymerization of microtubule subunits into active molecular motors by forming adducts with the alpha tubulin subunit ([@B98]; [Figure 2](#F2){ref-type="fig"}).

Chronic Ethanol Consumption Retards Triglyceride Breakdown (Lipolysis) and Fatty Acid Oxidation
-----------------------------------------------------------------------------------------------

Lipophagic degradation of LDs, yields free triglycerides and cholesteryl esters. These are hydrolyzed by lipases and esterases, respectively, generating free cholesterol, and high-energy fatty acids. Each fatty acid is activated by conjugation to coenzyme A (CoA), forming a fatty-acyl CoA, which is transported into the mitochondrion. There, it undergoes a stepwise series of beta (β) oxidations and cleavages, producing multiple two-carbon units of acetyl-CoA, which enter the Krebs cycle to generate ATP. Thus, the oxidative breakdown of one mole of palmitate, a C16 fatty acid, yields eight moles of acetyl CoA, to generate 96 moles of ATP. This is four-times more ATP than that yielded by the oxidation of one mole of glucose, a C6 monosaccharide ([@B19]).

Ethanol consumption impedes triglyceride (TG) breakdown, as demonstrated by Schott, et al. who reported that β-adrenergic activation of the cytosolic ATGL and phosphorylation of the hormone-sensitive lipase (HSL) are lower in hepatocytes from ethanol-fed rats than in cells from pair-fed controls ([@B84]). These findings are closely linked to a reduction in LD breakdown in these cells.

Furthermore, chronic ethanol consumption impairs the mitochondrial oxidation of fatty acids released from hydrolyzed TGs by causing mitochondrial depolarization ([@B122]) and by dysregulating the function of the peroxisome proliferator activated receptor alpha/retinoid X receptor (PPAR-α/RX receptor) a transcriptional regulator that governs expression of enzymes that catalyze FAO ([@B31]). Evidence suggests that such disruption by alcohol administration is caused, in part, by direct binding of metabolically-generated acetaldehyde to PPAR-α, thereby diminishing its ability to bind target DNA sequences used to transcribe mRNAs that encode FAO enzymes ([@B32]).

Chronic Ethanol Administration Lowers the Nuclear Content of Transcription Factor EB (TFEB)
-------------------------------------------------------------------------------------------

Transcriptional regulators of autophagy/lipophagy belong to the microphthalmia-associated/TFE subfamily of basic/helix-loop-helix/leucine zipper transcription factors. These include transcription factors EB and E3 (TFEB and TFE3) in mammals. TFEB is the major transcription factor which activates genes that encode proteins involved in autophagy, lysosome biogenesis and mitochondrial biogenesis ([@B90], [@B92]; [@B91]). It was also demonstrated that TFEB promotes lipophagy ([@B89]).

Our laboratory examined the levels of intranuclear (transcriptionally active) and cytosolic (inactive) TFEB in livers of C57Bl/6 mice subjected to acute and chronic ethanol administration. Interestingly, our analyses revealed that, compared with vehicle-gavaged control mice, TFEB nuclear content was elevated in livers of acutely-treated, ethanol- gavaged mice. These findings are consistent with similar studies conducted previously ([@B20]) and indicate that sudden hepatic oxidant stress in naïve animals enhances autophagy in liver, which was confirmed by changes in autophagy markers, LC3II and P62. Additionally, it is noteworthy that proteasome activity was unaffected in livers of acutely ethanol-gavaged mice. We obtained contrasting results, after subjecting mice to chronic ethanol feeding for 5--9 week. Liver nuclei of ethanol-fed mice exhibited lower nuclear TFEB content than pair-fed control mice Proteasome activity in livers of ethanol-fed animals was also significantly lower than pair-fed control mice ([@B105]).

Recently, we examined the recovery from alcohol-induced steatosis in 6 week ethanol-fed Wistar rats, some of which were withdrawn from ethanol and fed control diet for 7 days. [Figure 4A,B](#F4){ref-type="fig"} show that nuclear TFEB content in livers of ethanol-fed rats was three-fold lower than in pair-fed control rats, while the level of cytosolic TFEB in ethanol-fed rats was higher ([Figure 4C](#F4){ref-type="fig"}), despite the fact that the level of mRNA that encodes TFEB was twofold lower in ethanol-fed rats than controls (data not shown); see [@B104]. [Figure 4A,B](#F4){ref-type="fig"} also demonstrate that nuclear TFEB levels returned to normal after 7 days of refeeding the control diet. Furthermore, [Figure 4D](#F4){ref-type="fig"} illustrates a similar pattern of decline and restoration of proteasome activity in ethanol-fed rats, respectively, before and after 7 days of refeeding the control diet.

![Effect of chronic ethanol administration on the nuclear and cytosolic levels of TFEB in rats subjected chronic ethanol feeding and withdrawal. **(A)** Western blots of nuclear and cytosolic TFEB in livers of rats fed control diet ethanol diet and rats fed ethanol diet and then withdrawn from ethanol and fed control diet for 7 days. **(B)**--mean levels of nuclear TFEB, **(C)** mean levels of cytosolic TFEB, and **(D)** mean hepatic proteasome activities in the three groups of animals, as indicated (figure reproduced from Figure 4 by [@B104] with permission).](fphar-10-00495-g004){#F4}

The question that arises from these studies is what mechanism(s) is/are responsible for the decline in nuclear TFEB content in chronically ethanol-fed rats and mice? [Figure 5](#F5){ref-type="fig"} provides a likely scenario: The entry of TFEB into the nuclear compartment is blocked by its phosphorylation, catalyzed principally by the mechanistic target of rapamycin (mTOR), the "master kinase" that suppresses autophagy ([@B55]). Unphosphorylated TFEB in the cytosol can freely enter the nucleus to enhance coordinated lysosomal expression and regulation (CLEAR) gene transcription ([@B91]), while its inactive, phosphorylated form remains in the cytosol, along with unphosphorylated TFEB produced by *de novo* synthesis.

![Proposed model for the impairment of TFEB nuclear content by ethanol oxidation. **(A)** In the absence of ethanol, phosphorylated (inactive) TFEB (p-TFEB; yellow circles) is selectively ubiquitylated and degraded by the ubiquitin-proteasome system (UPS) in the cytosol, allowing translocation of active TFEB (green circles) into the nucleus to enhance transcription of CLEAR genes. **(B)** Chronic ethanol oxidation inhibits proteasome activity, which causes p-TFEP accumulation in the cytosol, resulting in heterodimer formation between pTFEB and active TFEB, thus preventing nuclear translocation of active TFEB and transcription of CLEAR genes (figure adapted from Figure 9 by [@B93] with permission).](fphar-10-00495-g005){#F5}

[@B93] demonstrated that the steady-state intracellular content of TFEB is principally regulated in the cytosol by the UPS. They report that a chaperone-dependent E3 ubiquitin ligase, STIP1 homology and U-Box containing protein 1 (STUB1) modulates TFEB content by preferentially ubiquitylating its phosphorylated form as a signal for degradation by the 26S proteasome. Thus, if either STUB1 or the 26S proteasome is inactivated, undegraded, phosphorylated TFEB accumulates in the cytosol thereby preventing autophagy gene activation by blocking the nuclear entry of unphosphoryated (active) TFEB. The latter scenario is possible because excess inactive TFEB monomers form heterodimers with unphosphorylated TFEB monomers ([@B93]), thereby blocking the nuclear entry of active TFEB to initiate autophagy. Because chronic ethanol consumption/oxidation generates oxidants that inhibit liver proteasome activity ([Figure 4C](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}; [@B24], [@B26]; [@B77]; [@B28]; [@B105]) such inhibition likely influences the ethanol-induced depletion of nuclear TFEB and the accumulation of cytosolic TFEB. This same scenario also partially explains why nuclear TFEB is either unaffected (or even rises) after acute ethanol treatment, as hepatic proteasome activity is unchanged by ethanol gavage ([@B106]). Additionally other factors prevail under acute and chronic conditions, as we described before ([@B105]) to explain these contrasting results.

Actions and Agents That Alleviate Ethanol-Induced And/Or Diet-Induced Steatosis
===============================================================================

Actions
-------

Withdrawal of ethanol from ethanol-fed rats ([@B104]) and humans rather rapidly and almost completely resolves their steatosis ([@B56]; [@B100]) to suggest that the absence of ethanol oxidation allows resumption of normal lipophagy after ethanol withdrawal.

Agents
------

The following are dietary and other natural or synthetic agents that are reported to enhance autophagy. None have been rigorously tested in humans with AUD, but some have undergone testing in ethanol-fed animals.

### Dietary Components

Caffeine is a well-known component of coffee ([@B34]). Caffeine is believed to block mTOR signaling thereby stimulating lipophagy and FAO in mice ([@B97]). Two meta-analyses in humans with NAFLD revealed that caffeine consumption alone does not affect liver fibrosis that arises from NAFLD. Interestingly, others report that regular coffee consumption provides protection against NAFLD-associated fibrosis ([@B71]; [@B94]). Most of the latter findings indicate that, in addition to caffeine, other non-caffeine components in coffee are hepatoprotective ([@B13]).

Zinc is an essential metal that has a hepatoprotective effect when it is supplemented in the diets of human AUD patients and ethanol-fed rodents ([@B72]). Dietary supplematation with zinc reportedly reactivates PPAR-α, to stimulate β-oxidation of fatty acids, thereby attenuating ethanol-induced steatosis ([@B44]). Zinc, is also critical for lysosome acidification and biogenesis in mammary tissue ([@B80]) to suggest that, by itself, zinc stimulates autophagy/lipophagy. The latter effect of zinc must be confirmed in liver.

### Plant-Derived Agents

Corosolic acid is a compound extracted from the leaves of the banaba tree (*Langertroemia speciosa* L). The chemical protects the liver from alcoholic-induced liver injury, in part by subduing apoptosis and restoring hepatic autophagy after activating the AMP-activated protein kinase (AMP kinase). The latter enzyme suppresses mTORC1 activity, which allows autophagy activation ([@B36]).

[@B63] tested the efficacy of quercitin, a flavonoid found in fruits, vegetables, red wine, and herbal medications, on autophagy in livers of 15 week ethanol-fed C57Bl/6 mice. They report that quercitin, administered by gavage, effectively reversed the ethanol-induced blockade of TFEB nuclear localization, restoring both lysosome function and autophagic flux to normal.

Salvianolic acid A is a is a water-soluble phenolic carboxylic acid extracted from *Salvia miltiorrhiza*. It has been tested in ethanol-fed rats and is reported to ablate alcohol-induced liver injury by reducing alcohol-induced steatosis by enhancing autophagosome-lysosome fusion after restoring lysosomal cathepsin activities ([@B95]).

### Repurposed Compounds

Lin et al. tested the effects of the autophagy inducers carbamazepine (an anti-seizure medication) and rapamycin (an immunosuppressant that blocks mTORC1). They also tested the lysosome inhibitor chloroquine, the antimalarial drug, which causes a rise in intralysosomal pH, on alcohol and diet-induced steatosis and injury (NAFLD). Their analyses revealed that treatment with the autophagy inducers attenuated fatty liver and injury in both models of AFLD and NAFLD. In contrast, chloroquine treatment exacerbated steatosis in these animals, but its effects were reversed by co-treatment with carbamezapine ([@B69]).

### Nanoformulated Compounds

A comprehensive study by [@B112] used a nanotechnology-enabled high throughput screen to test 15,000 compounds to identify those that activate TFEB. Three of these, digoxin, a cardiac glycoside used to treat atrial fibrillation, ikarugamycin, a natural antibacterial/anti-protozoan agent, used to treat infections, and alexidine dihydrochloride, an inhibitor of protein tyrosine phosphatase localized to the mitochondrion, activated TFEB, each by a distinct calcium-dependent mechanism. When the latter compounds were each formulated into nanoparticles and used to treat animals, each of them conferred hepatoprotection from diet-induced steatosis in mice and extended the lifespan of the roundworm *Caenorhabditis elegans* (*C elegans*). Whether these latter compounds would be effective agents to treat alcohol-induced fatty liver remains to be tested.

Summary and Future Directions
=============================

It is evident that autophagy is critical for maintaining normal liver function and it has a crucial role in ablating fatty liver disease that arises from excessive drinking. Although autophagy activity in the alcohol-induced fatty liver is affected by the duration of ethanol consumption/exposure, the amount of ethanol administered, and the way in which it is administered, there is solid evidence that chronic ethanol consumption retards the lipophagic/autophagic clearance of LDs that accumulate during the pathogenesis of alcohol-induced fatty liver. The reasons for retarded removal of LDs are threefold: (1) Ethanol oxidation disrupts the autophagic/lipophagic machinery (e.g., lysosomes) that degrade LDs; (2) alcohol-metabolism changes the phospholipid composition of the LD membrane, which, in turn, alters its content of resident proteins, conferring greater membrane resistance to lipophagy and lipolysis; and (3) ethanol metabolism thwarts the mitochondrial oxidation of fatty acids extracted from LDs by inhibiting PPAR-α and disrupting mitochondrial function.

While it is clearly evident that chronic alcohol consumption disrupts lipophagy, which contributes to alcohol-induced steatosis, the specific ethanol metabolite(s) that cause(s) such disruption(s) have/has yet be unequivocally identified. Strong circumstantial evidence, cited here, implicates metabolically-derived acetaldehyde as the offending agent. The challenges to confirming acetaldehyde as the sole autophagy disruptor are: (1) its volatility (bp = 21°C); (2) the high sensitivity required for its detection *in vivo* in its free and adducted forms. (3) detecting acetaldehyde or MAA adducts on specific autophagy/lipophagy-related proteins; and (4) defining whether such modifications influence the biological functions of these proteins.

Both acute and chronic alcohol consumption increase ROS production, which leads to oxidant stress. Our previous findings indicate that blocking acetaldehyde/ROS formation or enhancing their removal, avoids the disruptive effects of ethanol oxidation on autophagy in ethanol-metabolizing cells. Studies have clearly shown that ethanol oxidation significantly disrupts the degradative (lysosomal) phase of autophagy/lipophagy.

Abstinence from alcohol along with proper pharmacological ([@B43]) and behavioral therapies ([@B38]) can effectively minimize recidivism and reverse steatosis in people with AUDs. Our animal studies, revealed that ethanol withdrawal from ethanol-fed rats almost completely resolves their steatosis after 7 days ([@B104]). These findings also suggest that cessation of ethanol consumption restores lipophagy rates to normal, thereby accelerating the removal of excess LDs.

Finally, evidence, mostly from animal studies, but some human studies, suggest that caffeine/coffee, resveratrol, corosolic acid, zinc, carbamazepine, and rapamycin, individually activate autophagy/lipophagy and may also be used to prevent and treat alcohol-induced fatty liver. The clinical utility of these aforementioned compounds and of those tested recently ([@B112]) appear to have therapeutic promise but those that were most recently discovered to activate TFEB ([@B112]) must be tested for safety and efficacy in human trials.
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